1. Generics Bulletin
  2. >>Policy & Regulation

AAM Blasts Build Back Better But Bernstein Offers Balance

Discounted Drugs Could Disincentivize US Biosimilar Competition, Says AAM

 
• By Chloe Kent

Biosimilars could be affected significantly by Build Back Better’s drug price negotiations provision, but industry associations and analysts differ on just how much.

Joe Biden stands in front of a Build Back Better poster
Build Back Better's proposed price controls could have a negative affect on the biosimilars industry • Source: Alamy

The US Association for Accessible Medicines has continued to criticize the Biden administration’s proposed Build Back Better Act due to the negative affect it could have on the biosimilars industry. The organization maintains that, as it currently stands, allowing free biosimilar competition will achieve more savings for patients than Build Back Better’s price negotiation model.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Generics Bulletin

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.